Effect of COL4A1 Expression on the Survival of Neoadjuvant Chemotherapy Breast Cancer Patients

Wang, Shin-Mae; Chen, Po‐Ming; Sung, Yu-Wen; Huang, Wei-Chieh; Huang, Hui-Ting; Chu, Pei‐Yi

doi:10.1155/2020/5209695

Cited by 9 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results indicated that the expression levels of COL4A1 in glioma tissues were significantly higher than those in normal brain tissues. This is supported by previous reports that COL4A1 expression is increased in malignant tumors (16,24,25,28). For instance, COL4A1 expression is also increased in numerous types of malignant tumor tissue (such as esophageal squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma of the bladder and breast cancer) and has an important impact on the occurrence and development of cancer (16,20,24,28).…”

Section: Discussionsupporting

confidence: 85%

“…This is supported by previous reports that COL4A1 expression is increased in malignant tumors (16,24,25,28). For instance, COL4A1 expression is also increased in numerous types of malignant tumor tissue (such as esophageal squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma of the bladder and breast cancer) and has an important impact on the occurrence and development of cancer (16,20,24,28). Of note, COL4A1 has also been reported to be increased in LGG.…”

Section: Discussionsupporting

confidence: 83%

“…Various studies have indicated that COL4A1 is involved in the pathological process of a variety of cancer types and has a key role in their occurrence, development and metastasis (24)(25)(26).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

COL4A1 as a novel oncogene associated with the clinical characteristics of malignancy predicts poor prognosis in glioma

Wang

Liu

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

Studies have indicated that collagen α-1 (IV) chain (COL4A1) has an indispensable regulatory role in the complex pathological mechanisms of numerous types of malignant tumor. However, its role in the development of glioma has remained elusive. Therefore, the present study sought to determine the association between the expression levels of COL4A1 and the clinical characteristics of gliomas by analyzing large samples. First, analysis of thousands of glioma tissue samples collected from the Gene expression profiling interactive analysis, Gene Expression Omnibus database, the Ivy glioblastoma atlas, The Human Protein Atlas, Chinese Glioma Genome Atlas and The Cancer Genome Atlas. In addition, glioma tissues and normal brain tissues from patients with glioma and epilepsy undergoing surgical resection were collected. These samples, which were subjected to a variety of different detection techniques (including sequencing data, chip data, reverse transcription-quantitative PCR, cell lines and tissue samples, in situ hybridization and immunology) revealed that COL4A1 expression was not only increased at the mRNA level but also at the protein level as compared with that in normal brain tissue. Furthermore, Kaplan-Meier analysis revealed that COL4A1 expression was associated with reduced overall survival of patients, particularly those with World Health Organization grade III glioma. Receiver operating characteristic analysis suggested that COL4A1 had a moderate diagnostic value for glioma. In addition, the Mann-Whitney U-test or Kruskal-Wallis test indicated that the expression levels of COL4A1 were positively associated with the histological type and historical grade of the tumor, patient age, 'Primary, Recurrent, Secondary' type and the chemotherapy status, and negatively associated with isocitrate dehydrogenase mutation and 1p19q co-deletion (P<0.001). Gene-set enrichment analysis indicated that overexpression of COL4A1 promoted cancer-associated pathways, such as the JAK/STAT signaling pathway and cell cycle regulation. Finally, an MTT assay, immunohistochemical analysis of the cell cycle regulator KI67 and a wound-healing assay further confirmed that knockdown of COL4A1 inhibited the proliferation and migration ability of glioma cells. In conclusion, COL4A1, as a novel oncogene, is a marker for poor prognosis in patients with glioma. The present study expanded the understanding of the pathogenesis of glioma and identified COL4A1 as a potential target for the diagnosis and treatment of gliomas.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionsupporting

confidence: 83%

See 1 more Smart Citation

COL4A1 as a novel oncogene associated with the clinical characteristics of malignancy predicts poor prognosis in glioma

Wang

Liu

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Sayyad et al demonstrated the role of Sdc1 in promoting brain metastasis in BC [ 36 ]. Several studies have demonstrated that COL4A1 expression could be used as a biomarker for superior prognosis in BC patients receiving neoadjuvant chemotherapy [ 37 ], while epigallocatechin-3-gallate (EGCG) exerted antitumor effects by restoring nine key genes, including COL4A1, in myeloid-derived suppressor cells (MDSCs) [ 37 ]. TGF β 1-activated cancer-associated fibroblasts (CAFs) promote BC growth and metastasis in part through autophagy [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Establishment and Analysis of an Individualized EMT-Related Gene Signature for the Prognosis of Breast Cancer in Female Patients

et al. 2022

View full text Add to dashboard Cite

Background. The current high mortality rate of female breast cancer (BC) patients emphasizes the necessity of identifying powerful and reliable prognostic signatures in BC patients. Epithelial-mesenchymal transition (EMT) was reported to be associated with the development of BC. The purpose of this study was to identify prognostic biomarkers that predict overall survival (OS) in female BC patients by integrating data from TCGA database. Method. We first downloaded the dataset in TCGA and identified gene signatures by overlapping candidate genes. Differential analysis was performed to find differential EMT-related genes. Univariate regression analysis was then performed to identify candidate prognostic variables. We then developed a prognostic model by multivariate analysis to predict OS. Calibration curves, receiver operating characteristics (ROC) curves, C -index, and decision curve analysis (DCA) were used to test the veracity of the prognostic model. Result. In this study, we identified and validated a prognostic model integrating age and six genes (CD44, P3H1, SDC1, COL4A1, TGFβ1, and SERPINE1). C -index values for BC patients were 0.672 (95% CI 0.611–0.732) and 0.692 (95% CI 0.586–0.798) in the training cohort and test set, respectively. The calibration curve and the DCA curve show the good predictive performance of the model. Conclusion. This study offered a robust predictive model for OS prediction in female BC patients and may provide a more accurate treatment strategy and personalized therapy in the future.

show abstract

“…Collagen type IV α1 chain (COL4A1), a type of collagen that belongs to the type IV collagen family, is a key component of the basement membrane and several studies have found that it acts as a cancer-promoting factor in several types of cancer (9)(10)(11)(12). Recent studies have found that COL4A1 is abnormally expressed in invasive ductal carcinoma of breast and bladder tumors and is associated with tumor invasion and metastasis (13,14). Furthermore, COL4A1 is reported to be upregulated in patients with OSCC (15).…”

Section: Introductionmentioning

confidence: 99%

COL4A1 promotes the proliferation and migration of oral squamous cell carcinoma cells by binding to NID1

Tian

Sun

et al. 2023

Exp Ther Med

View full text Add to dashboard Cite

Collagen type IV α1 chain (COL4A1) is a collagen protein that acts as a tumor-promoting factor in several types of cancer. However, the role and the potential mechanisms involving COL4A1 in oral squamous cell carcinoma (OSCC) remain unclear. Using reverse transcription-quantitative PCR and western blotting, the expression levels of COL4A1 and (nidogen-1) NID1 in OSCC cells were assessed. Cell Counting Kit-8, EdU staining and colony formation assays were used to evaluate cell proliferation. Cell migration and invasion were assessed using wound healing and Transwell invasion assays, respectively. The expression levels of proteins involved in epithelial-mesenchymal transition (EMT) were assessed using western blotting. In addition, the association between COL4A1 and NID1 was analyzed using TNMplot and the STRING database and verified by co-immunoprecipitation analysis. COL4A1 expression was found to be significantly increased in OSCC cells. Knockdown of COL4A1 expression decreased SCC-4 cell proliferation, migration and invasion, as well as the progression of EMT. In addition, COL4A1 was shown to be significantly positively associated with NID1 in OSCC and to bind to NID1. NID1 overexpression reversed the inhibitory effects of COL4A1 knockdown on cell proliferation, migration and invasion as well as on the progression of EMT in OSCC cells. In summary, the present findings demonstrated that COL4A1 promoted cell proliferation and migration as well as the progression of EMT in OSCC cells by binding to NID1, highlighting a potential avenue for therapeutic management of OSCC.

show abstract

Effect of COL4A1 Expression on the Survival of Neoadjuvant Chemotherapy Breast Cancer Patients

Cited by 9 publications

References 23 publications

COL4A1 as a novel oncogene associated with the clinical characteristics of malignancy predicts poor prognosis in glioma

COL4A1 as a novel oncogene associated with the clinical characteristics of malignancy predicts poor prognosis in glioma

Establishment and Analysis of an Individualized EMT-Related Gene Signature for the Prognosis of Breast Cancer in Female Patients

COL4A1 promotes the proliferation and migration of oral squamous cell carcinoma cells by binding to NID1

Contact Info

Product

Resources

About